| Name | Title | Contact Details |
|---|
Wellabe is a U.S.-based insurance provider with a rich history dating back to 1929. Originally founded as American Republic Insurance Company, it rebranded in 2023 following a merger of six subsidiaries under American Enterprise Group, Inc. The name "Wellabe" reflects its commitment to reliability and long-term customer support. The company specializes in health and financial protection solutions, offering a range of insurance products. These include Medicare Supplement insurance, Hospital Indemnity coverage, Preneed Insurance for funeral expenses, Short-term Care Insurance, and Final Expense Life Insurance. Wellabe also partners with organizations like Start Hearing®, VSP® Individual Vision Plans, and CancerEDGE™ to enhance its supplemental health services. The company primarily serves older adults and retirees, focusing on their needs for aging, chronic conditions, and end-of-life planning. Wellabe is dedicated to customer-centric values, emphasizing integrity and community engagement.
Tanenholz & Associates is a Washington, D.C. based law firm specializing in all aspects of discovery, from initial consultation to the end-to-end management of large-scale document reviews. With years of big-firm litigation experience, Tanenholz & Associates understands that well-planned and high quality document review can both minimize litigation costs and maximize litigation efficiencies. Providing flexible teams of skilled contract attorneys led by experienced senior associates, Tanenholz & Associates is uniquely equipped to manage your discovery needs.
Grenova™ is an innovative company that is revolutionizing lab consumables through high-quality waste reduction solutions. Our mission is to lower costs in the laboratory industry and reduce biohazard waste in the environment by delivering groundbreaking approaches in dealing with plastic consumables. Every year, over 5 million pounds of plastic pipette tips are disposed of in landfills globally after a single use. This drives significant environmental pollution and unnecessary costs. The typical laboratory consumes several thousand pipette tips every day for samples and assay procedures, due to the lack of options for safely cleaning plastic consumables. Such high consumption of plastic tips adds $25,000 to $1.5 million in annual operational costs for laboratories worldwide. At Grenova™, we know that high consumption of plastic tips is an excessive, avoidable operational cost for companies and a significant contributor to environmental pollution. This is why we decided to create devices that enable labs to wash and recycle pipette tips in large quantities. Grenova devices offer labs the option to reuse plastic tips several times, cutting associated costs by up to 90%. Grenova devices are safe for both the user and the environment, without producing hazardous waste or gases.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.